INTRODUCTION

Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV2) is a new virus causing a zoonosis originating from bats (COroNaVirus Disease-19, COVID-19), as recently reported in the literature. Following its outbreak in China, SARS-CoV2 has led to a worldwide spread, being declared by the WHO as a pandemic condition on March 11, 2020 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). As of June 21, 2020, 8 938 672 infected patients have been identified worldwide, 467 114 (5.2%) of whom died (https://www.worldometers.info/coronavirus/).

The leading cause of mortality is the acute respiratory distress syndrome (ARDS) following viral pneumonia. ARDS can translate into a devastating end-stage lung disease for which treatment options are limited. Furthermore, many ARDS cases may progress to pulmonary fibrosis, another clinically devastating lung disease for which also limited curative strategies are available. Therefore, understanding the immunological mechanisms of virus-related ARDS represents a high-priority research topic.

When epidemics occur, transplant patients raise concern due to their vulnerability to infections. Whether immunosuppressants modify the transition from SARS-CoV2 contagion to pneumonia and, ultimately, ARDS is not known yet.

The role of the immunological mechanisms causing coronavirus (CoV)-related ARDS in the context of transplantation can be seen as...
a "bench to bedside" type experiment on the impact of immunosuppressive drugs in the course of the respiratory disease.

The pathogenesis of CoV-related ARDS includes complement and coagulation cascade activation, and proinflammatory and profibrotic cytokine responses. After infecting the pneumocytes, CoV induces a massive signaling response in infected lungs, favoring thereby the release of several proinflammatory cytokines and chemokines, including IL-6, TNFα, IL-1β, and CCL2. These molecules recruit inflammatory cells to the site of infection, such as neutrophils and cytotoxic T cells. These cells may damage tissues leading to vascular leakage and fibrosis formation.1

In some cases, the inflammatory status can become systemic, leading to a cytokine storm syndrome with the characteristics of a secondary hemophagocytic lymphohistiocytosis. Therefore, the use of immunosuppressants such as corticosteroids or anti-cytokine drugs like IL-1 blocker (anakinra) and IL-6 receptor blocker (tocilizumab) has been proposed.2

With the present work, we aimed to review the existing literature on the impact of immunosuppression on coronaviruses infections and the development of severe lower respiratory tract disease. Secondly, we retrieved and summarized the recently published literature describing the course of CoV infections in transplant recipients.

2 | METHODS

A review of the literature reporting on coronavirus infections in immunocompromised patients was conducted. In particular, we focused on the relationship with the most frequently employed immunosuppressants in the management of transplant recipients (namely: steroids, calcineurin inhibitors, and mycophenolic acid). Secondly, an electronic search was performed to identify all studies reporting on the management of immunosuppression in transplant recipients infected with SARS-CoV2. The PubMed/MEDLINE database was searched on May 6th, 2020. The search strategy was “SARS-CoV2” OR “COVID-19” AND “transplantation”. We included all the studies describing the management of immunosuppression in transplant recipients. Potential case duplicates were ruled out by analysis of demographic characteristics of the included patients and country and institution of origin of the reports.

3 | IMMUNOCOMPROMISED PATIENTS AND CORONAVIRUSES

Several studies reported the specific role of an immunocompromised status as a possible risk factor for CoV-related pneumonia. A study based on 85 immunocompromised vs 1152 non-immunocompromised children did not show a different prevalence of CoV-related pneumonia and severe pneumonia (22% vs 26% and 15% vs 11%, respectively). However, the immunocompromised status was a risk factor for severe respiratory disease.3

Another study on five Rhesus macaques showed that immunosuppression with cyclophosphamide and dexamethasone leads to a significantly higher level of the Middle East respiratory syndrome (MERS)-CoV replication in the respiratory tissues. Despite this increased viral replication, pathologic findings in the lungs were significantly lower than in immunosuppressed animals.4

A Korean study reported atypical presentations of MERS-CoV infection in three immunocompromised patients with delayed development of symptoms, a prolonged incubation period, and a persistent viral shedding without clinical deterioration.5 All these peculiar presentations were probably influenced by the underlying immunological status of the patients, including the use of immunosuppressants.5

More recently, a systematic review analyzed 110 immunosuppressed patients infected with SARS-CoV-2, mostly presenting cancer, along with transplantation and immunodeficiency. The results revealed a tendency toward a favorable disease course, as compared to the general population. The authors concluded that this phenomenon might be explained by a possible protective role of a weaker immune response, determining a milder disease presentation and, thus, underdiagnosis.6

4 | STEROIDS AND CoV-RELATED PULMONARY DISEASE: PROS AND CONS

Understanding the potential harm or benefit of steroids in CoV-related disease is of immediate clinical importance. In theory, steroids may play a role in suppressing virus-driven lung inflammation, although increasing the time of viral clearance and viral shedding.

In Table 1, the effect of steroids on coronavirus clearance and patient survival is displayed.

| Virus       | Impact on viral clearance                                      | Impact on survival            |
|-------------|----------------------------------------------------------------|-------------------------------|
| MERS-CoV    | Delayed clearance of viral RNA from respiratory tract7        | 90-d mortality OR = 0.8 (95% CI = 0.5-1.1; P = .12)7              |
| SARS-CoV    | Delayed clearance of viral RNA from the blood8,9               | In case of severe pneumonia, protective effect (0/60 deaths vs 11/130; P = .01810 |
| SARS-CoV2   | Delayed clearance of viral RNA from respiratory tract11        | HR = 0.38 (95% CI = 0.2-0.7)12 |

Note: The steroids adopted were: hydrocortisone, methylprednisolone, dexamethasone, and prednisolone.

Abbreviations: CoV, coronavirus; HR, hazard ratio; MERS, Middle East respiratory syndrome; SARS, severe acute respiratory syndrome.
In a retrospective study, including 309 adults with MERS-CoV-caused ARDS, the administration of steroids did not lead to different 90-day mortality (odds ratio = 0.8, 95% CI = 0.5-1.1; \( P = .12\)). Conversely, delayed clearance of viral RNA from the respiratory tract secretions was reported (hazard ratio = 0.4, 95% CI = 0.2-0.7; \( P = .0005\)).

A meta-analysis based on the steroidal treatment of SARS-CoV identified four studies only with conclusive data, all of them showing a harmful effect. The adverse reported effects were (a) worsening of SARS-related psychosis, (b) increase of viremia in non-critically ill patients, and (c) development of diabetes and avascular necrosis.

A Chinese study, including 190 patients with severe SARS-related pneumonia, randomly allocated the patients to four different treatment regimens. The best results were obtained in the cohort of 60 patients receiving early high-dose steroids and nasal continuous airway-positive pressure ventilation (zero deaths vs 8.5% cumulatively reported in the other three groups; \( P = .018\)).

Up to now, the studies related to SARS-CoV2 treatment are preliminary. One study from China, including 292-positive SARS-CoV2 patients, compared steroid against non-steroid-treated groups. In the steroid group, a longer duration of viral RNA detection was revealed in the oro-pharyngeal (15 vs 8 days, \( P = .013\)) and feces swabs (20 vs 11 days, \( P < .001\)).

Another Chinese study on SARS-CoV2-related ARDS showed that treatment with methylprednisolone decreased the risk of death from 61.8% to 46.0% (HR = 0.38; 95% CI = 0.20-0.72). A third study from China on 46 severe patients with COVID-19 pneumonia showed better results in the subgroup of 26 cases receiving low-dose methylprednisolone (1-2 mg/kg/d iv for 5-7 days). The steroid group had a faster improvement of SpO2, shorter interval of oxygen supplementation (8 vs 14 days; \( P < .001\)), and an inferior need for mechanical ventilation (\( P = .05\)).

Two recently published letters related to the use of steroids express controversial opinions; one considers the use of steroids as a contraindication, the other as a (cautiously) useful tool for severely diseased SARS-CoV2 patients. Current interim guidance from WHO on clinical management of severe acute respiratory infection (released March 13, 2020) advises not to use steroids unless indicated for another reason.

In transplanted patients, steroids are used mainly as induction and anti-rejection agents and always less often as a "maintenance therapy". The recently published clinical recommendations from the American Association for the Study of Liver Diseases (AASLD) have reported that minimization of high-dose steroid dosage is recommended in immunosuppressed patients with COVID-19 but maintaining a sufficient dosage to avoid adrenal insufficiency. Another statement recommended initiating therapy with steroids in patients with liver disease with or without COVID-19 who have strong indications for treatment like autoimmune hepatitis or graft rejection.

5 | OTHER IMMUNOSUPPRESSANTS AND CORONAVIRUSES: FROM BENCH TO BEDSIDE?

Various studies explored the impact of calcineurin inhibitors (CNI) cyclosporine (CyA) and tacrolimus (TAC) and their non-immunosuppressive derivatives on the in vitro and in vivo replication of coronaviruses.

CyA and TAC bind to different cellular cyclophilins in order to inhibit calcineurin, a calcium-calmodulin-activated serine/threonine-specific phosphatase. The calcineurin inhibition blocks the translocation of the nuclear factor of activated T cells from the cytosol into the nucleus, thereby preventing the transcription of several genes encoding for the key cytokines involved in the immunological mechanisms, like interleukin-2. Apart from this mechanism, cyclophilins are required by several viruses for their replication.

Interestingly, inhibition of cyclophilin by CyA can block the replication of CoV of all genera, including SARS-CoV, human CoV-229E, human CoV-NL-63, feline CoV, as well as avian infectious bronchitis virus. Similarly, TAC strongly inhibits the growth of human coronaviruses SARS-CoV, human CoV-NL63, and human CoV-229E.

In vitro and human ex vivo explant cultures reported the synergic effect of two immunomodulatory agents, namely interferon-alpha and cyclosporine, as critical agents for the reduction of MERS-CoV replication.

Mycophenolic acid has also been shown to block the papain-like protease of MERS-CoV, therefore, blocking the in vitro replication of the virus.

Due to the small number of reported transplant cases experiencing CoV infections, no clear clinical evidence exists on the real impact of the immunosuppressive drugs in the clinical practice yet. The AASLD interestingly stated that: "the immune response may be the main driver for pulmonary injury due to COVID-19 and that immunosuppression may be protective". However, the recommendations for good clinical practice from most scientific societies are based on common sense rather than on evidence, as the latter is still lacking.

6 | CoV-RELATED DISEASE AND SURVIVAL IN TRANSPLANTED PATIENTS

Only anecdotal experiences of solid organ transplant recipients experiencing CoV infections have been reported during SARS and MERS epidemics. Remarkably, among the 774 and 912 deaths reported in the two outbreaks of SARS in 2002 and MERS in 2012, respectively, only two transplanted cases were described in the literature. Likely, this number is an underestimation of reality, but it could reflect that transplant patients did not suffer from more severe forms of pulmonary disease compared to the general population during the previous CoV epidemics.

Conversely, a more significant number of case reports and small series are consistently being published during the SARS-CoV-2...
| Author/Country/N Ref | Author/Country/N Ref | Author/Country/N Ref | Author/Country/N Ref | Author/Country/N Ref |
|----------------------|----------------------|----------------------|----------------------|----------------------|
| **LAI et al.**        | **LAI et al.**        | **LAI et al.**        | **LAI et al.**        | **LAI et al.**        |
| **TABLE 2**           | **Solid organ transplant patients experiencing SARS-CoV-2-related disease: details of immunosuppression modification** |
| **Author/Country/N**  | **Ref**              | **Age (y)**           | **Sex**              | **Transplant**        |
| **Time from transplant** | **Baseline IS**      | **IS after CoV infection** |
| **LAI et al.**         | **[185x1499]**       | **[49x699]**          | **[164x710]**        | **[49x683]**          |
| **20**                 | **[27]**             | **[59]**              | **[M 80%]**          | **Kidney 20**         |
| **20**                 | **[27]**             | **[13 y]**            | **[TAC 95% MMF 70% Ster 65% mTORi 10%]** | **IS stop/Ster iv** |
| **36**                 | **[28]**             | **[60]**              | **[M 72%]**          | **Kidney 36**         |
| **13 y**               |                      | **[TAC 97% Ster 94% MMF 86%]** | **MMF stop 86% TAC stop 21%** |
| **7**                  | **[29]**             | **[48]**              | **[M]**              | **Kidney**            |
| **[59*]**              |                      | **[1 y]**             | **[TAC MMF Ster]**   | **TAC MMF Ster**      |
| **[3 y]**              |                      | **[TAC MMF Ster]**    | **[TAC MMF Ster]**   | **TAC MMF Ster**      |
| **[1 mo]**             |                      | **[TAC MMF Ster]**    | **[MMF stop]**       | **MMF stop**          |
| **[3 y]**              |                      | **[TAC MMF Ster]**    | **[MMF stop]**       | **MMF stop**          |
| **[3 y]**              |                      | **[TAC AZA Ster]**    | **[AZA stop/TAC ↓ Ster ↑]** | **AZA stop/TAC ↓ Ster ↑** |
| **60**                 | **[30]**             | **[>65]**             | **[M]**              | **Livers 3**          |
| **[>10 y]**            |                      | **[CsA = 2 TAC = 1]** | **[NR]**             | **NR**                |
| **[NR]**               |                      | **[CsA or TAC]**      | **[NR]**             | **NR**                |
| **1**                  | **[31]**             | **[44]**              | **[M]**              | **Kidney**            |
| **[7 y]**              |                      | **[TAC MMF Ster]**    | **[TAC ↓ Ster ↓]**   | **TAC ↓ Ster ↓**      |
| **103; Liver 23; Heart 13; Lung 9** | **[NR]**      | **[NR]**              | **[NR]**             | **NR**                |
| **1**                  | **[32]**             | **[NR]**              | **[NR]**             | **NR**                |
| **2**                  | **[33]**             | **[32]**              | **[M]**              | **Kidney**            |
| **[2 y]**              |                      | **[TAC MMF Ster]**    | **[TAC ↓ MMF ↓ Ster]** | **TAC MMF stop**      |
| **15**                 | **[34]**             | **[49]**              | **[M]**              | **Kidney**            |
| **[6 y]**              |                      | **[TAC MMF Ster]**    | **[TAC MMF Ster]**   | **TAC MMF Ster**      |
| **18**                 | **[35]**             | **[51]**              | **[M 65%]**          | **Kidney**            |
| **[49 mo]**            |                      | **[TAC 93% MMF 80% Ster 67% Belatacept 13%]** | **MMF stop 71%/All IS stop 14% TAC/MMF Ster 7%** |
| **18**                 | **[36]**             | **[71]**              | **[M 72%]**          | **Kidney 8; Liver 6; Heart 4** |
| **[9.3 y]**            |                      | **[TAC 50% MMF 56% Ster 61% mTOR 28% CsA 17%]** | **TAC stop/ mTOR initiated = 2** |
| **2**                  | **[37]**             | **[75]**              | **[M]**              | **Kidney**            |
| **[10 y]**             |                      | **[TAC MMF Ster]**    | **[TAC MMF stop]**   | **TAC MMF stop**      |
| **1**                  | **[38]**             | **[50]**              | **[M]**              | **Kidney**            |
| **[4 y]**              |                      | **[TAC EVE Ster]**    | **[TAC EVE stop]**   | **TAC EVE stop**      |
| **1**                  | **[39]**             | **[52]**              | **[M]**              | **Kidney**            |
| **[8 mo]**             |                      | **[TAC MMF Ster]**    | **[TAC MMF stop]**   | **TAC MMF stop**      |
| **2**                  | **[40]**             | **[51]**              | **[M]**              | **Bone marrow**       |
| **[8 mo]**             |                      | **[CsA]**             | **[CsA stop Ster iv]** | **CsA stop Ster iv** |
| **1**                  | **[41]**             | **[59]**              | **[M]**              | **Liver**             |
| **[2 y]**              |                      | **[TAC MMF]**         | **[TAC ↓ MMF ↓ Ster]** | **TAC ↓ MMF ↓ Ster** |
| **1**                  | **[42]**             | **[57]**              | **[M]**              | **Kidney**            |
| **[8 mo]**             |                      | **[TAC MMF]**         | **[MMF ↓ TAC ↓]**    | **MMF ↓ TAC ↓**      |
| **4**                  | **[43]**             | **[54]**              | **[M]**              | **Kidney**            |
| **[20 y]**             |                      | **[TAC MMF]**         | **[Ster initiated/ TAC ↓ MMF stop]** | **Ster initiated/ TAC ↓ MMF stop** |
| **1**                  | **[44]**             | **[51]**              | **[M]**              | **Heart**             |
| **[17 y]**             |                      | **[TAC MMF]**         | **[TAC MMF stop/Ster iv]** | **TAC MMF stop/Ster iv** |
| **1**                  | **[45]**             | **[50]**              | **[M]**              | **Liver**             |
| **[2 y]**              |                      | **[TAC]**             | **[TAC stop/Ster iv]** | **TAC stop/Ster iv** |
| **2**                  | **[46]**             | **[61]**              | **[M]**              | **Liver**             |
| **[9 d]**              |                      | **[Basiliximab TAC Ster]** | **[NR]**             | **NR**                |
| **1**                  | **[47]**             | **[58]**              | **[M]**              | **Kidney**            |
| **[3 y]**              |                      | **[BLT MMF Ster]**    | **[BLT MMF stop/CsA initiated]** | **BLT MMF stop/CsA initiated** |
| **2**                  | **[48]**             | **[77]**              | **[M]**              | **Heart**             |
| **[17 y]**             |                      | **[SIR MMF]**         | **[TAC initiated/SIR MMF stop]** | **TAC initiated/SIR MMF stop** |
| **1**                  | **[49]**             | **[35]**              | **[M]**              | **Kidney**            |
| **[4 y]**              |                      | **[EVE Ster]**        | **[EVE ↓ and later stop CsA stop]** | **EVE ↓ and later stop CsA stop** |
| **1**                  | **[50]**             | **[29]**              | **[M]**              | **Kidney**            |
| **[1 y]**              |                      | **[MMF CsA Ster]**    | **[None]**           | **None**              |
| **1**                  | **[51]**             | **[37]**              | **[M]**              | **Liver**             |
| **[19 d]**             |                      | **[TAC Ster]**        | **[TAC Ster ↓]**     | **TAC Ster ↓**        |

(Continues)
pandemics, many of which also reporting the details on the immune-suppressive regimen management (Table 2).27-55

A total of 284 COVID-19 transplant cases have been reported to date: specifically, 210 kidneys, 42 livers, 21 hearts, 10 lungs, and one bone marrow cases. The median age reported was 52 years. The cases came from the US (n = 206), Italy (n = 32), Spain (n = 19), China (n = 17), United Kingdom (n = 7), France (n = 1), Germany (n = 1), and the Nederland (n = 1). One study contains results from a nation-based survey from the USA on kidney transplantation.32 Therefore, overlap with cases from the other articles coming from US institutions could not be ruled out.28,31,35,39,42,43

Out of the 130 patients in whom information on the final clinical course were provided, 30 (23.1%) deaths were reported. Globally, 67 of 280 (23.9%) cases required invasive ventilation (Table 3).27-55 Therefore, overlap with cases from the other articles coming from US institutions could not be ruled out.28,31,35,39,42,43

Out of the 130 patients in whom information on the final clinical course were provided, 30 (23.1%) deaths were reported. Globally, 67 of 280 (23.9%) cases required invasive ventilation (Table 3).27-55

According to these data, the current COVID-19 pandemics has sadly affected the transplant population much more in-depth respect to the SARS and MERS outbreaks. The cases came from the US (n = 206), Italy (n = 32), Spain (n = 19), China (n = 17), United Kingdom (n = 7), France (n = 1), Germany (n = 1), and the Nederland (n = 1). One study contains results from a nation-based survey from the USA on kidney transplantation.32 Therefore, overlap with cases from the other articles coming from US institutions could not be ruled out.28,31,35,39,42,43

Data on COVID-19 in transplanted patients are still sparse, and the opportunity to obtain a global picture is still limited. A more reliable estimate of how lethal SARS-CoV-2 is to transplant recipients could be obtained after matching them by age and comorbidities with the general population. Up to now, only a large study focused on pediatric transplantation has been published exploring the potential prevalence of COVID-19 in transplanted cases. In detail, the preliminary experience of the pediatric Transplant Center of the Hospital Papa Giovanni XXIII in Bergamo, Italy, located in the "red zone" of the Italian outbreak, was reported.54 Interestingly, this large series based on 700 children did not report any case of clinical pulmonary disease and only three-positive cases. These data suggest that children, similarly to the general pediatric population, should develop a less aggressive course of COVID-19 also when immunosuppressed.56

| Author/Country/N | Ref | Age (y) | Sex | Transplant | Time from transplant | Baseline IS | IS after CoV infection |
|------------------|-----|---------|-----|------------|---------------------|------------|-----------------------|
| Seminari Italy N = 1 | 52 | 50 | M | Kidney | 4 y | TAC MMF | None |
| Zhang China N = 5 | 53 | 38 | M | Kidney | NR | TAC MMF Ster | MMF stop |
| | 64 | M | Kidney | TAC MMF Ster | MMF stop/MMF stop/Ster stop 16 d/TAC initiated |
| | 37 | F | Kidney | TAC MMF Ster | MMF stop |
| | 47 | M | Kidney | TAC MMF Ster | MMF stop/Ster stop 4 d |
| | 38 | M | Kidney | TAC MMF Ster | NR |
| Zhong China N = 2 | 54 | 37 | M | Liver | 9 d | TAC Ster | TAC stop |
| Zhu China N = 1 | 55 | 52 | M | Kidney | 12 y | TAC MMF | TAC ↓/MMF stop/Ster iv |

Abbreviations: AZA, azathioprine; BLT, belatacept; CHKT, combined heart-kidney transplant; CsA, cyclosporin-A; EVE, everolimus; F, female; IS, immunosuppression; M, male; MMF, mycophenolate mofetil; N, number of cases; NR, not reported; Ref, reference; SIR, sirolimus; Ster, steroids; TAC, tacrolimus; y, years.

*Median.

TABLE 2 (Continued)
| Author/Country/N | Ref | CoV-related treatment | Antibacterial treatment | PGGO | ARDS | ICU | Invasive ventilation | Death (d) |
|-----------------|-----|-----------------------|------------------------|------|------|-----|----------------------|-----------|
| Alberici Italy N = 20 | 27 | HQC 95% LPV/r 79% | Antibiotics 55%; cephalosporins 64% beta-lactams 36% fluoroquinolones 25%; carbapenems 10%; glycopeptides 5% | Yes: uni = 35% | NR | Yes | 10% | Yes 25% (day 15*) |
| Akalin USA N = 36 | 28 | HCQ 86% LRL 21% TCZ 7% | AZM 46% | Yes 96% | NR | NR | Yes 31% | Yes 28% |
| Banerjee UK N = 7 | 29 | None | None | NR | NR | No | No | No |
| None | None | Broad spectrum | Yes | Yes | Yes | Yes | Yes | Intubated |
| OTV | Broad spectrum | Yes | Yes | Yes | Yes | NR |
| NR | Broad spectrum + TMP-SXT | NR | Yes | NR | NR |
| NR | NR | NR | No | No | No |
| Bhoori Italy N = 6 | 30 | NR | NR | Yes | Yes | Yes | Yes | Yes 3-12 |
| Billah USA N = 1 | 31 | NR | NR | No | No | No | No | No |
| Boyarsky USA N = 148 | 32 | HCQ 78% TCZ 31% RDV 25% | AZM 47% | NR | NR | NR | Yes 25% | Yes |
| Bussalino Italy N = 1 | 33 | HCQ OTV | CPT | No | No | No | No | No |
| Chen China N = 1 | 34 | RBV IVIG | MXF | Yes | No | Yes | No | No |
| Columbia NY USA N = 15 | 35 | HCQ 27% HCQ + AZM 60% TCZ 7% | NR | Yes 50% | NR | NR | Yes 27% | Yes 7% |
| Fernández-Ruiz Spain N = 18 | 36 | LPV/r = 9 HCQ = 8 | NR | Yes 72% | NR | Yes 11% | Yes 11% | Yes 28% |
| Gandolfi Italy N = 2 | 37 | HCQ LPV/r DRV-COBI | NR | Yes | Yes | No | No | Yes 5 |
| Guillen Spain N = 1 | 38 | LPV/r HCQ IFN-β | CPT MEM | Yes | Yes | Yes | Yes | Intubated |
| Hsu USA N = 1 | 39 | HCQ DRV-COBI | NR | Yes | Yes | No | No | No |
| Huang China N = 2 | 40 | LPV/r IVIG | MXF CTR LZD MEM CAS OTV ECMO | Yes | Yes | Yes | Yes | Yes 22 |
| Huang China N = 1 | 41 | IFN-α UMV LPV/r ECOMO | TZP CFP CAS | Yes | Yes | Yes | Yes | Yes 45 |
| Johnson USA N = 1 | 42 | HCQ | FEP AZM | Yes | No | NR | No | No |
| Kates USA N = 4 | 43 | HCQ AZM | CTR | Yes | No | No | No | No |
| Nil | NR | No | Yes | No | No |
| Nil | NR | No | No | No | No |
| Nil | NR | No | No | No | No |
| Li China N = 2 | 44 | RBV MXF GCV IVIG | LVX | Yes | No | No | No | No |
| NR | NR | No | No | No | No |
| Liu China N = 1 | 45 | OTV UMV LPV/r IFN-α IVIG | CFP | Yes | No | No | No | No |
| Maggi Italy N = 2 | 46 | NR | NR | NR | NR | NR | NR | No | Yes 30 |

(Continues)
Table 3 (Continued)

| Author/Country/N  | Ref | CoV-related treatment | Antibacterial treatment | PGGO | ARDS | ICU | Invasive ventilation | Death (d) |
|-------------------|-----|-----------------------|-------------------------|------|------|-----|----------------------|-----------|
| Marx France N = 1 | 47  | NR                    | NR                      | Yes  | No   | No  | No                   | No        |
| Mathies Germany N = 1 | 48 | HCQ GCV               | TZIP TMP-SXT            | Yes  | Yes  | Yes | No                   | No        |
| Meziyerh Netherlands N = 1 | 49 | HCQ LPV/r            | CTR                     | Yes  | Yes  | Yes | Yes                  | No        |
| Ning China N = 1  | 50  | LPV/r IVIG           | MXF TMP-SXT             | Yes  | No   | No  | No                   | No        |
| Qin China N = 1   | 51  | OTV h-GCSF IVIG      | NR                      | Yes  | No   | NR  | No                   | No        |
| Seminati Italy N = 1 | 52 | None                  | CTR                     | Yes  | No   | No  | No                   | No        |
| Zhang China N = 5 | 53  | OTV UMV              | NR                      | Yes  | No   | NR  | No                   | No        |
| Ning China N = 1  | 54  | OTV                   | CFP                     | Yes  | No   | Yes | No                   | No        |
| Zhu China N = 1   | 55  | UMY IFN-α IVIG       | MXF                     | Yes  | No   | No  | No                   | No        |

*Median

Abbreviations: ARDS, acute respiratory distress syndrome; AZM, azithromycin; BIPM, biapenem; CAS, caspofungin; CFM, cefixime; CFP, ceferoporen-sulbactam; CPT, cefotaroline; CTR, Ceftriaxone; DOX, doxycycline; DRV-COBI, darunavir-cobicistat; DRV-RTV, darunavir/ritonavir; ECMO, extracorporeal membrane oxygenation; FEP, cefepime; GCV, ganciclovir; HCQ, hydroxychloroquine; h-GCSF, human granulocyte colony-stimulating factor; ICU, intensive care unit; IFN, interferon; IPM, imipenem; IVIG, intravenously injected immunoglobin; LPV/r, lopinavir/ritonavir; LRL, leronlimab; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MXF, moxifloxacin; not reported; OTV, oseltamivir; PPGO, patchy ground-glass opacity; RBV, ribavirin; RDV, remdesivir; Ref, reference; TCZ, tocilizumab; TMP-SXT, Trimethoprim-Sulfamethoxazole; TZIP, piperacillin-tazobactam; umifenovir; UMV; VAN, vancomycin.

7 | CoV-RELATED DISEASE AND IMMUNOSUPPRESSION CHANGES IN TRANSPLANTED PATIENTS

Data on the modification of immunosuppressive regimens in transplanted patients experiencing the SARS-CoV-2 infection are reported in Table 2.27-55

Before infection, the most common baseline maintenance immunosuppression was CNI, MMF with or without steroids. In the 126 cases in which the post-COVID-19 immunosuppression therapy was detailed, the most common form of immunosuppression modification was the discontinuation of the antimitabolites MMF or azathioprine (n = 41, 32.5%), followed by the discontinuation of the entire immunosuppression regimen (n = 37, 29.4%), the discontinuation of the CNI (n = 17, 13.5%), and the dose reduction of all the immunosuppressive drugs (n = 10, 7.9%). Remarkably, 116/126 (92.1%) cases maintained or reintroduced steroids during the infection. In some cases, steroids were switched from oral to intravenous form following discontinuation or reduction of all the other drugs (n = 26/126, 20.6%).

From the data above, a divergence between clinical reality and societal recommendations emerges.

As an example, the discontinuation of azathioprine, MMF, or CNI seems more common than just the dose reduction that was suggested by the AASLD in cases of lymphopenia, fever, or worsening pneumonia caused by COVID-19.17

Similarly, in consensus-based guidance derived from individual information of 19 transplant societies, only the reduction—rather than the discontinuation—of immunosuppression was suggested (7/19 society consensus) in the absence of a recent history of transplant rejection.24

In the recent COVID-19 literature, complete immunosuppression withdrawal is often encountered, although this is probably magnified by the overreporting of severe COVID-19 cases. Expectedly, an even larger yet unreported group of patients with uneventful infections might maintain or lower their immunosuppression.

Cross-sectional studies are required to unfold real-life clinical practice with immunosuppression management. As of now, we can only observe that a general consent exists on a slight reduction of the immunosuppressive load in CoV-positive patients with moderate clinical status, while the reported clinical experiences show a trend toward a more aggressive immunosuppressive reduction in severe cases.

8 | FINAL CONSIDERATIONS

SARS-CoV2 can cause a fearsome disease evolving in ARDS, pulmonary fibrosis, and death. The role of the transplant physician is to correctly diagnose and manage the infected transplanted patient,
Considerations on immunosuppression (IS) in transplanted patients with COVID-19

| Considerations on IS management                                                                 | Ref. |
|------------------------------------------------------------------------------------------------|------|
| #1 Immunosuppressors (ie, steroids) may present more intense and prolonged virus shedding.   | 7-9,11 |
| #2 The reduced virus clearance can potentially increase the risk of transmission to contacts, also including healthcare workers. | 57   |
| #3 Steroids should be carefully used in light of their potential benefits and harms.         | 15   |
| #4 Steroids should be prudently used in critically ill patients with COVID-19 pneumonia.    | 15,17 |
| #5 In transplanted patients regularly using steroids, their further use should be cautious.   | 15   |
| #6 Steroid dosage should be low-to-moderate (≤0.5-1 mg/kg per day of methylprednisolone or equivalent) and the duration should be short (≤7 d). | 15   |
| #7 In vitro studies showed that calcineurin inhibitors or mycophenolic acid derivates reduce viral replication. | 18-23 |
| #8 No clinical evidence exists on the potentially positive impact of calcineurin inhibitors or mycophenolic acid derivates in transplanted patients with COVID-19. | -    |
| #9 In case of moderate illness, only an IS reduction should be considered.                    | 17,24 |
| #10 In severely ill patients with high risk of ARDS and bacterial superinfections, IS suspension apart low-dose steroids should be considered. | 25-55 |
| #11 No studies exist on the potential interaction between immunosuppressors and the different antiviral drugs: therefore, immunosuppressant plasma levels should be often checked. | 58   |
| #12 Interferon-beta and (hydroxy)chloroquine should be cautiously adopted in transplanted patients for the risk of rejection and toxicity. | 59,60 |
| #13 Consult the drug interactions documents on the possible interactions using experimental COVID-19 therapies. | 17   |
| #14 Monitor new studies of antiviral and immunomodulatory approaches for COVID-19 treatment. | 17   |

Abbreviations: ARDS, Acute respiratory distress syndrome; COVID-19, Coronavirus disease-19; IS, immunosuppression.

The reported literature shows that CoV-positive transplanted patients treated with immunosuppressants such as steroids may present more intense and prolonged virus shedding, thereby increasing potentially the risk of transmission to contacts, including healthcare workers.7-9,11,57

On the other side, the use of steroids in the treatment of ARDS showed controversial results, and moderate use is suggested. The cautious approach proposed by Shang et al seems reasonable. Steroid use should be (a) carefully weighed case by case in light of the potential benefits and harms; (b) prudently administered in critically ill patients with COVID-19 pneumonia; (c) as well as in patients regularly using steroids (such as transplanted patients), further use of steroids should be cautious; and, (d) the dosage should be low-to-moderate (≤0.5-1 mg/kg/d methylprednisolone or equivalent), and the duration should be short (≤7 days).15

Unfortunately, due to the lack of knowledge concerning COVID-19 in transplanted patients, it is not possible to provide evidence-based recommendations regarding the use of immunosuppressants. The observed results in the present study mainly draw on extrapolation from scarce data on other viral diseases, in vitro data, case reports, small series, and international guidelines based on sound clinical practice and common sense. However, we attempted to summarize some considerations extrapolated from published data (Table 4). The limitation of our work resides in the evolving body of literature on COVID-19 and transplantation, which is released daily and precludes a systematic approach in the review process. Besides, the heterogeneity of the reported cases and the limited information provided within the articles we analyzed, renders any conclusions speculative and should not be intended as guidance on patient management. Nevertheless, we intended to provide transplant physicians with a useful snapshot of the available reports on the topic and to frame this clinical data with the knowledge around previous coronavirus infections in immunocompromised and transplanted patients.

As for the other immunosuppressive drugs, no clinical shreds of evidence exist concerning their impact in transplanted COVID-19 patients. Theoretically, in vitro studies showed that the use of CNI or mycophenolic acid might be a strategy to reduce viral replication.17-23 Since no clinical studies exist on this aspect, caution is recommended when managing immunosuppressors in COVID-19-positive patients. In the presence of moderate illness, only a reduction of the immunosuppressive load should be considered.17,24 In severely ill patients with a high risk of ARDS and potential bacterial superinfections, several small clinical shreds of evidence reported the decision to discontinue the immunosuppression drugs.25-55

No studies exist on the potential interaction between immunosuppressants and the different antiviral drugs, including remdesivir, lopinavir/ritonavir, darunavir/ cobicistat, interferon–beta, and (hydroxy)chloroquine used in the treatment of COVID-19.58 However, increased trough levels of tacrolimus have been observed after patients received antiviral treatment, with subsequent nephrotoxicity. Consequently, it is essential to measure frequently the
immunosuppressant plasma levels with the intent to prevent over-immunosuppression and to cautiously adopt or even avoid drugs such as interferon-beta and (hydroxy)chloroquine in transplanted patients which could lead to rejection or toxicity.\textsuperscript{59,60} In this context, it should be important to consult the University of Liverpool Drug Interactions Group document on the possible interactions using experimental COVID-19 Therapies (https://www.covid19-druginteractions.org), and to monitor the new studies of antiviral and immunomodulatory approaches for the treatment of COVID-19.\textsuperscript{17}

**CONFLICT OF INTEREST**
The authors have no conflicts of interest to declare about the present study.

**AUTHORS CONTRIBUTIONS**
QL, GS, and JL were responsible for the conception, design, analysis, and writing of the study; QL, GS, GB, and DG were involved with the collection and interpretation of data; MR and JL participated in data management, review, and editing of the manuscript.

**ORCID**
Quirino Lai https://orcid.org/0000-0003-1487-3235

**REFERENCES**

1. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235:185-195.

2. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

3. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state. J Pediatric Infect Dis Soc. 2019;8:21-28.

4. Prescott J, Falzarano D, de Wit E, et al. Pathogenicity and viral shedding of MERS-CoV in Immunocompromised rhesus macaques. Front Immunol. 2018;9:205.

5. Kim SH, Ko JH, Park GE, et al. Atypical presentations of MERS-CoV infection in immunocompromised hosts. J Infect Chemother. 2017;23:769-773.

6. Chiara Minotti C, Tirelli F, Barbieri E, Giaquinto C, Donà D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81(1):e61-e66.

7. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.

8. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.

9. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304-309.

10. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52:715-720.

11. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J. 2020;133(9):1039-1043.

12. Wu C, Chen X, Cai Y, et al. Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934.

13. Wang Y, Jiang W, He Q, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020;5(1):57.

14. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-475.

15. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683-684.

16. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Mar 13, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed Mar 26, 2020)

17. Fix OK, Hameed B, Fontana RJ, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020. https://doi.org/10.1002/hep.31281. [Epub ahead of print].

18. Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5:1250-1260.

19. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7:e1002331.

20. Carbajo-Lozoya J, Müller MA, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165:112-117.

21. Li HS, Kuok DIT, Cheung MC, et al. Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antiviral Res. 2018;155:89-96.

22. Carbajo-Lozoya J, Ma-Lauer Y, Maleševič M, et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 2014;184:44-53.

23. Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papaïn-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9-16.

24. Ritschl PV, Nevermann N, Wiering L, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a By-proxy Society Recommendation Consensus approach. Am J Transplant. 2020;20(7):1826-1836.

25. AlGhamdi M, Mushtaq F, Awn N, Shalhoub S. MERS-CoV infection in two renal transplant recipients: case report. Am J Transplant. 2015;15:1101-1104.

26. Kumar D, Tellier R, Drake R, Levy G, Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003;3:977-981.

27. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int. 2020;97(6):1083-1088.

28. Akalin E, Azzi Y, Bartaš R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475-2477.

29. Banerjee D, Popoola D, Shah S, Ster IC, Quan V, Shanish M. COVID-19 infection in kidney transplant recipients [published online ahead of print, 2020 Apr 9]. Kidney Int. 2020;97(6):1076-1082.

30. Bhoo ri S, Rossi RE, Citterio D, Mazzaferr o V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020;5(6):532-533.
31. Billah M, Santeusiano A, Delaney V, Cravedi P, Farouk SS. A catabolic state in a kidney transplant recipient with COVID-19. Transpl Int. 2020. https://doi.org/10.1111/tri.13635. [Epub ahead of print].

32. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020;20(7):1809-1818.

33. Bussalino E, De Maria A, Russo R, Paolotti E. Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV-2 pneumonia: a case report [published online ahead of print, 2020 Apr 13]. Am J Transplant. 2020;20:1922-1924. https://doi.org/10.1111/ajt.15920

34. Chen S, Yin Q, Shi H, et al. A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China. Am J Transplant. 2020;20(7):1869-1874.

35. Columbia University Kidney Transplant Program. Early description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York [published online ahead of print, 2020 Apr 21]. J Am Soc Nephrol. 2020;31:1150–1156. https://doi.org/10.1681/ASN.2020030375

36. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am J Transplant. 2020;20(7):1849-1858.

37. Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020;20(7):1941-1943.

38. Hsu JJ, Gaynor P, Kamath M, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant. 2020;20(7):1911-1915.

39. Guillaud E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant. 2020;20(7):1875-1878.

40. Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients—report of 2 cases. Am J Transplant. 2020;20(7):1879-1881.

41. Huang JF, Zheng KI, George J, et al. Fatal outcome in a liver transplant recipient SARS-CoV2 pneumonia: a case report [published online ahead of print, 2020 Apr 24]. Am J Transplant. 2020;20:1840-1848. https://doi.org/10.1111/ajt.15948

42. Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in renal transplant recipients: a review of recent literature and case supporting corticosteroid-sparing immunosuppression. Pharmacotherapy. 2020;40(6):517-524.

43. Kates OS, Fisher CE, Stankiewicz-Karita HC, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients [published online ahead of print, 2020 Apr 13]. Am J Transplant. 2020;20:1916-1921.

44. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020;39(5):496-497.

45. Liu B, Wang Y, Zhao Y, Shi H, Zeng F, Chen Z. Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient. Am J Transplant. 2020;20(7):1891-1895.

46. Maggi U, De Carlis L, Yiu D, et al. The impact of the COVID-19 outbreak on liver transplantation programmes in Northern Italy [published online ahead of print, 2020 Apr 24]. Am J Transplant. 2020;20:1840-1848. https://doi.org/10.1111/ajt.15948

47. Marx D, Moulin B, Fafi-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020;20(7):1944-1946.

48. Mathies D, Rauschning D, Wagner U, et al. A Case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old male with heart transplant [published online ahead of print, 2020 Apr 21]. Am J Transplant. 2020;20(7):1925-1929.

49. Mezleyer S, Zwart TC, van Etten RW, et al. Severe COVID-19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant. 2020;20(7):1896-1901.

50. Ning L, Liu L, Li W, et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report. Am J Transplant. 2020;20(7):1864-1868.

51. Qin J, Wang H, Qin X, et al. Perioperative presentation of COVID-19 disease in a liver transplant recipient. Hepatology. 2020. https://doi.org/10.1002/hep.31257. [Epub ahead of print].

52. Seminari E, Colaneri M, Sambo M, et al. SARS CoV2 infection in a renal transplanted patients. A case report [published online ahead of print, 2020 Apr 3]. Am J Transplant. 2020;20 1882-1884. https://doi.org/10.1111/ajt.15902

53. Zhang H, Chen Y, Yuan Q, et al. Identification of kidney transplant recipients with coronavirus disease 2019. Eur Urol. 2020;77(6):742-747.

54. Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients [published online ahead of print, 2020 Apr 13]. Am J Transplant. 2020;20(7):1916-1921.

55. Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. 2020;20(7):1859-1863.

56. D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26(6):832-834.

57. Michaels MG, La Hoz RM, Danziger-Isakov L, et al. Coronavirus disease 2019: Implications of emerging infections for transplantation. Am J Transplant. 2020;20(7):1768-1772.

58. Kumar D, Manuel O, Natori Y, et al. COVID-19: A global transplant perspective on successfully navigating a pandemic. Am J Transplant. 2020;20(7):1773-1779.

59. Assadiasl S, Shahi A, Salehi S, Afzali S, Amirzargar A. Interferon regulatory factors: where to stand in transplantation. Transpl Immunol. 2018;51:76-80.

60. Giner Galván V, Oltra MR, Rueda D, Esteban MJ, Redón J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol. 2007;26:971-972.

How to cite this article: Lai Q, Spoletini G, Bianco G, et al. SARS-CoV2 and immunosuppression: A double-edged sword. Transpl Infect Dis. 2020;00:e13404. https://doi.org/10.1111/tid.13404